The Enhanced Pancreatic Cancer Profiling for Individualized Care (EPPIC) team, is hoping to improve personalized treatments for patients across Canada with pancreatic ductal adenocarcinoma (PDAC), a particularly deadly form of cancer, over the next five years. Dr. David Schaeffer, head of Anatomic Pathology at Vancouver General Hospital (VGH) and an assistant professor at UBC, says the idea is to help improve personalized treatment. Read more . . .
Canadian scientists are teaming up with the Terry Fox Research Institute (TFRI) to lead a new $5-million personalized treatment initiative.